J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sandberg, A
Right arrow Articles by Bergstrand, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sandberg, A
Right arrow Articles by Bergstrand, R
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Pharmacology, 1990; 30:S2-16
© 1990 the American College of Clinical Pharmacology

Articles

Pharmacokinetic and biopharmaceutic aspects of once daily treatment with metoprolol CR/ZOK: a review article

A Sandberg, B Abrahamsson, CG Regardh, I Wieselgren, and R Bergstrand

In the development of a new controlled release preparation and its subsequent assessment there are a number of factors that need to be considered both related to the drug itself and to the pharmaceutical preparation. This review describes the biopharmaceutical and pharmacokinetic properties of metoprolol CR/ZOK, a recently introduced formulation of a widely used beta 1-selective adrenoceptor antagonist intended for once daily usage. The metoprolol CR/ZOK preparation provides reproducible dissolution and absorption properties resulting in stable plasma concentrations with minimum fluctuations over a 24-hour dosage interval. This has been shown in extensive studies comprising over 200 healthy volunteers. Considerations for a new drug preparation such as bioavailability and variability in relation to a standard treatment and the clinical significance of taking the drug with food and in increasing doses, are potential concerns that do not seem to be a problem for the therapeutic use of metoprolol CR/ZOK. Furthermore, the pharmacokinetic data achieved in young healthy subjects appear to be relevant for the treatment of patients, as shown by the consistent plasma concentration profiles obtained in elderly and in hypertensive patients.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J CARDIOVASC PHARMACOL THERHome page
J. L. Bauman and R. L. Talbert
Pharmacodynamics of{beta}-Blockers in Heart Failure: Lessons from the Carvedilol Or Metoprolol European Trial
Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 2004; 9(2): 117 - 128.
[Abstract] [PDF]

Home page
 The Annals of PharmacotherapyHome page
H. J Tangeman and J H. Patterson
Extended-Release Metoprolol Succinate in Chronic Heart Failure
Ann. Pharmacother., May 1, 2003; 37(5): 701 - 710.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
A Kardos, V Long, J Bryant, J Singh, P Sleight, and B Casadei
Lipophilic versus hydrophilic beta 1 blockers and the cardiac sympatho-vagal balance during stress and daily activity in patients after acute myocardial infarction
Heart, February 1, 1998; 79(2): 153 - 160.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the American College of Clinical Pharmacology